A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma (Q80332147)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

main subject

phase I clinical trial

1 reference

1 reference

1 reference

John C Elkas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

William E Winter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Mildred R Chernofsky

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Jan Sunde

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Michael A Bidus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Sarah Bernstein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

G Scott Rose

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

22 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

422-427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Phase I and pharmacologic study of topotecan in patients with impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.08.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2006.08.011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16996118%20AND%20SRC:MED&resulttype=core&format=json